SUPN Q2 2022 Earnings — Supernus Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena

SUPNSupernus Pharmaceuticals, Inc.

$3B

Q2 2022 Earnings

Healthcare Drug Manufacturers - Specialty & Generic

Income Statement

Revenue

$170M+20.3% YoY

Gross Profit

$150M88.0% margin

Operating Income

$11M6.7% margin

Net Income

$8M4.6% margin

EPS (Diluted)

$0.14

QoQ Revenue Growth

+11.5%

Cash Flow

Operating Cash Flow

$71M

Free Cash Flow

$72M

Stock-Based Comp.

$4M

Balance Sheet

Total Assets

$1.7B

Total Liabilities

$854M

Stockholders' Equity

$841M

Cash & Equivalents

$173M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$170M	$141M	+20.3%
Gross Profit	$150M	$116M	+28.6%
Operating Income	$11M	$34M	-66.7%
Net Income	$8M	$24M	-66.9%

Revenue Segments

Product

$165M49%

Trokendi Xr

$72M21%

Oxtellar X R

$30M9%

GOCOVRI

$25M7%

APOKYN

$20M6%

Qelbree

$11M3%

Manufactured Product, Other

$8M2%

Royalty

$5M1%